BioMarin Pharma Enters Growth Phase and 4 Stock Analyses to Track

BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) is believed by RBC Capital to be entering a new growth phase towards eventual profitability, since it has one of the best pipelines among midcap biotech companies. The firm has seen a 50 percent or higher chance that the company could possibly be acquired over the next several years, and it keeps its Outperform rating and a $55 price target on the stock.

Ingersoll-Rand Plc (NYSE:IR): Credit Suisse recommends purchasing Ingersoll-Rand prior to the expected results from its strategic review. The firm doesn’t view expectations as being high, and it thinks that the update will solidify margin and return potential. Shares have an Outperform rating and a $51 price target, up from $47.

Catalysts are critical to discovering winning stocks. Check out our newest CHEAT SHEET stock picks now.

Broadcom Corp. (NASDAQ:BRCM): After the firm attended Broadcom’s Analyst Day, RBC Capital is convinced that the company’s upcoming products “appear ready for prime time.” The firm predicts that the company has the ability to potentially gain market share and it keeps its Outperform rating.

LMI Aerospace Inc. (NASDAQ:LMIA) has been added to the short-term buy list at Deutsche Bank.

Noble Corp. (NYSE:NE) price target has been reduced by Susquehanna in order to show a lack of contracting activity in its rig fleet. The firm keeps its Positive rating, but based on expectations for increased drilling activity in the Gulf of Mexico.

Don’t Miss: Behold! Here’s Another Buy Rating for Apple.